Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914. The phase 3 CheckMate 914 clinical ...
Relapse outcomes were similar in patients with high-risk renal cell carcinoma treated with Opdivo and with observation before and after surgery. Adding Opdivo (nivolumab) before and after surgery did ...
Bristol Myers Squibb is offering a detailed look at pivotal data showing that an under-the-skin version of its PD-1 inhibitor Opdivo works as well as the original intravenous formulation in kidney ...
Results from the Phase 3 CheckMate -67T trial will be presented in a late-breaking oral presentation at ASCO GU 2024. 3 Summer "Power Patterns" Are About to Trigger (One With 90% Win Rate) - Get The ...
Exelixis EXEL announced encouraging results from an expansion cohort of the early to mid-stage study of its next-generation oral TKI, zanzalintinib, in combination with either Bristol Myers' BMY ...
Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results